Professional
Added to YB: 2025-08-08
Pitch date: 2025-06-30
EXAS [bullish]
Exact Sciences Corporation
+95.44%
current return
Author Info
No bio for this author
Company Info
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Market Cap
$19.7B
Pitch Price
$52.85
Price Target
N/A
Dividend
N/A
EV/EBITDA
187.48
P/E
-93.68
EV/Sales
6.55
Sector
Biotechnology
Category
growth
Baron Health Care Fund New Position: Exact Sciences Corporation
EXAS (new position): Molecular diagnostics company with Cologuard stool tests for early colorectal cancer detection. 106M eligible US adults, 50% not screened. 13% market share vs invasive colonoscopies. Stock down on slowed adoption, Guardant blood test fears & Supreme Court coverage case - all concerns now easing. Reacceleration expected.
Read full article (1 min)